Published in Hepatitis Weekly, July 11th, 2005
The data showed statistically significant superiority in protective antibody response and robustness of protective effect after three vaccinations when compared to GlaxoSmithKline's Engerix-B vaccine in an older adult population that is difficult to immunize with conventional vaccine. The primary endpoint of the ongoing phase II/III trial is seroprotection 4 weeks after administration of the third dose.
"The clear demonstration of superiority of our HBV vaccine in a population with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.